Brian W. Brannigan

Harvard University

Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

h-index23

i10-index25

Publications64

Citations21,838

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last latest available · showing 20 of 30

Supplementary Methods from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate CancerPreprint
2023-04-03
Supplementary Figures 1-6 from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate CancerPreprint
2023-04-03
Supplementary Tables 1-2 from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer
2023-04-03
Data from Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator ClaspinPreprint
2023-04-03
Data from Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator ClaspinPreprint
2023-04-03
Supplementary Methods from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate CancerPreprint
2023-04-03
Supplementary Figures 1-6 from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate CancerPreprint
2023-04-03
Data from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate CancerPreprint
2023-04-03
Data from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate CancerPreprint
2023-04-03
Supplementary Tables 1-2 from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer
2023-04-03
Supplementary Figure 6 from Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase InhibitorsPreprint
2023-03-30
Supplementary Figure 7 from Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase InhibitorsPreprint
2023-03-30
Supplementary Figure 5 from Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase InhibitorsPreprint
2023-03-30
Supplementary Methods, Figures 1-8, Tables 1-3 from A Genome-Wide Screen for Microdeletions Reveals Disruption of Polarity Complex Genes in Diverse Human CancersPreprint
2023-03-30
Supplementary Figure 4 from Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase InhibitorsPreprint
2023-03-30
Supplementary Figure 3 from Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase InhibitorsPreprint
2023-03-30
Supplementary Methods, Figures 1-8, Tables 1-3 from A Genome-Wide Screen for Microdeletions Reveals Disruption of Polarity Complex Genes in Diverse Human CancersPreprint
2023-03-30
Data from Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase InhibitorsPreprint
2023-03-30
Data from A Genome-Wide Screen for Microdeletions Reveals Disruption of Polarity Complex Genes in Diverse Human CancersPreprint
2023-03-30
Data from Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase InhibitorsPreprint
2023-03-30

Open author page on OpenAlex →